Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort

Danyang SunDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Junxun MaDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Jinliang WangDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Fan ZhangDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Lijie WangDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Sujie ZhangDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Guangying ChenDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Xiaoyan LiDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Wushuang DuDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Pengfei CuiDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]

Yi HuDepartment of Oncology, Chinese PLA General Hospital, Beijing, China, [email protected]Correspondence[email protected]

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Chen-Xu Ni, Yu Zhao, Hong Qian, Hui Fu, Yu-Ying Yan, Yu-Shuang Qiu, Can-Can Zhou, Fang Huang, Fu-Ming Shen, Dong-Jie Li & Qing Xu. (2023) Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report. Frontiers in Pharmacology 14.
Crossref

Wenhao Luo, Yawen Wang & Taiping Zhang. (2022) Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer. Cancer Cell International 22:1.
Crossref

Dong Song, Xuejing Yang, Xin Guo & Hu Sun. (2022) Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer. Immunotherapy 14:16, pages 1307-1313.
Crossref

Qinjun Chen, Tao Sun & Chen Jiang. (2021) Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy. Nano-Micro Letters 13:1.
Crossref

Seyed Hossein Kiaie, Mohammad Javad Sanaei, Masoud Heshmati, Zahra Asadzadeh, Iman Azimi, Saleh Hadidi, Reza Jafari & Behzad Baradaran. (2021) Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharmaceutica Sinica B 11:5, pages 1083-1097.
Crossref

Giulia Marelli, Louisa S Chard Dunmall, Ming Yuan, Carmela Di Gioia, Jinxin Miao, Zhenguo Cheng, Zhongxian Zhang, Peng Liu, Jahangir Ahmed, Rathi Gangeswaran, Nicholas Lemoine & Yaohe Wang. (2021) A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer. Journal for ImmunoTherapy of Cancer 9:1, pages e001624.
Crossref

Chin-King Looi, Felicia Fei-Lei Chung, Chee-Onn Leong, Shew-Fung Wong, Rozita Rosli & Chun-Wai Mai. (2019) Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date